(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)
Three years ago, there were high hopes for NuPathe Inc. (PATH), a specialty pharmaceutical company that develops therapeutics for neurological and psychiatric disorders. NuPathe went public on August 6, 2010. Shares reached $10.22, an all-time high on the first day of trading. Unfortunately, the company's shares have traded down, way down to reach a low of $1.57 on October 22, 2013. Since then, the stock has slowly but steadily increased to over $2 a share.
NuPathe has the only US Food and Drug Administration (FDA) approved migraine patch, Zecuity (sumatriptan). Zecuity is a single-use, battery-powered patch that actively delivers ...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|